Back to Browse Journals » Pharmacogenomics and Personalized Medicine » Volume 5

Individualization of antiretroviral therapy

Authors Pavlos R, Phillips EJ

Published Date December 2011 Volume 2012:5 Pages 1—17

DOI http://dx.doi.org/10.2147/PGPM.S15303

Published 29 December 2011

Rebecca Pavlos, Elizabeth J Phillips
Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia

Abstract: Antiretroviral therapy (ART) has evolved considerably over the last three decades. From the early days of monotherapy with high toxicities and pill burdens, through to larger pill burdens and more potent combination therapies, and finally, from 2005 and beyond where we now have the choice of low pill burdens and once-daily therapies. More convenient and less toxic regimens are also becoming available, even in resource-poor settings. An understanding of the individual variation in response to ART, both efficacy and toxicity, has evolved over this time. The strong association of the major histocompatibility class I allele HLA-B*5701 and abacavir hypersensitivity, and its translation and use in routine HIV clinical practice as a predictive marker with 100% negative predictive value, has been a success story and a notable example of the challenges and triumphs in bringing pharmacogenetics to the clinic. In real clinical practice, however, it is going to be the exception rather than the rule that individual biomarkers will definitively guide patient therapy. The need for individualized approaches to ART has been further increased by the importance of non-AIDS comorbidities in HIV clinical practice. In the future, the ideal utilization of the individualized approach to ART will likely consist of a combined approach using a combination of knowledge of drug, virus, and host (pharmacogenetic and pharmacoecologic [factors in the individual's environment that may be dynamic over time]) information to guide the truly personalized prescription. This review will focus on our knowledge of the pharmacogenetics of the efficacy and toxicity of currently available antiretroviral agents and the current and potential utility of such information and approaches in present and future HIV clinical care.

Keywords: HIV, pharmacogenetics, pharmacogenomics, personalized medicine, antiretroviral

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

High mobility group box-1 and its clinical value in breast cancer

Sun S, Zhang W, Cui Z, Chen Q, Xie P, Zhou C, Liu B, Peng X, Zhang Y

OncoTargets and Therapy 2015, 8:413-419

Published Date: 12 February 2015

Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus

Beltrán LM, Rubio-Navarro A, Amaro-Villalobos JM, Egido J, García-Puig J, Moreno JA

Vascular Health and Risk Management 2015, 11:35-48

Published Date: 6 January 2015

Isolated posterior uveal effusion: expanding the spectrum of the uveal effusion syndrome

Pautler SE, Browning DJ

Clinical Ophthalmology 2015, 9:43-49

Published Date: 30 December 2014

Determination of factors controlling the particle size and entrapment efficiency of noscapine in PEG/PLA nanoparticles using artificial neural networks

Shalaby KS, Soliman ME, Casettari L, Bonacucina G, Cespi M, Palmieri GF, Sammour OA, El Shamy AA

International Journal of Nanomedicine 2014, 9:4953-4964

Published Date: 23 October 2014

In vivo MRI tracking of iron oxide nanoparticle-labeled human mesenchymal stem cells in limb ischemia

Li XX, Li KA, Qin JB, Ye KC, Yang XR, Li WM, Xie QS, Jiang ME, Zhang GX, Lu XW.

International Journal of Nanomedicine 2013, 8:1063-1073

Published Date: 12 March 2013

Intensive care unit-related fluconazole use in Spain and Germany: patient characteristics and outcomes of a prospective multicenter longitudinal observational study

Wissing H, Ballus J, Bingold TM, Nocea G, Krobot KJ, Kaskel P, Kumar RN, Mavros P

Infection and Drug Resistance 2013, 6:15-25

Published Date: 30 January 2013

Lebrikizumab in the personalized management of asthma

Thomson NC, Patel M, Smith AD

Biologics: Targets and Therapy 2012, 6:329-335

Published Date: 14 September 2012

Increased reactive oxygen metabolites is associated with cardiovascular risk factors and vascular endothelial damage in middle-aged Japanese subjects

Sugiura T, Dohi Y, Takase H, Yamashita S, Tanaka S, Kimura G

Vascular Health and Risk Management 2011, 7:475-482

Published Date: 19 July 2011

Improving adherence with inhaler therapy in COPD

Suzanne C Lareau, Barbara P Yawn

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:401-406

Published Date: 24 November 2010